For our Saturday edition of The Daily Dive, host Cassandra Leah sits down with that of JR Rhan, founder and co-CEO of Mind Medicine (NEO: MMED). JR joins us to discuss operating in the mental health space, why the firm elected to study MDMA and LSD, and the stigma associated with such compounds that the company has had to work through.
Mind Medicine, or MindMed as it is often referred to, is one of the leading psychedelic medicine firms in the pharmaceutical space. The company is focused on discovering, developing, and deploying psychedelic-inspired medicines along with experiential therapies for addiction and mental illness. MindMed currently has a pipeline with a variety of substances that includes psilocybin, LSD, DMT, Ibogaine derivatives, and MDMA.
Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.